Trials / Completed
CompletedNCT00088192
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eyetech Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium |
Timeline
- Start date
- 2004-07-01
- First posted
- 2004-07-22
- Last updated
- 2005-08-30
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088192. Inclusion in this directory is not an endorsement.